Online table I. Classification of biopharmaceuticals according to ATC codes

ATC code / Chemical/pharmacological/therapeutic subgroups or substance name
First level / 2nd, 3rd, 4th or 5th level
A, Alimentary tract and metabolism / A10A / Insulins and analogues
A10BX04 / Exenatide
A10BX07 / Liraglutide
A16AB / Enzymes
B, Blood and blood forming organs / B01AB02 / Antithrombine III
B01AC13 / Abciximab
B01AD / Antithrombotic agents, enzymes
B01AE01 / Desirudin
B01AE02 / Lepirudin
B02AB02 / Alpha-1 antitrypsin
B02AB03 / C1-inhibitor
B02BB / Fibrinogen
B02BD / Blood coagulation factors
B02BX04 / Romiplostim
B03X / Other antianemic preparations
B05AA01 / Albumin
B06AA / Enzymes
C, Cardiovascular system / C01DX19 / Nesiritide
D, Dermatologicals / D03AX06 / Becaplermine
G, Genito uriny system and sex hormones / G03GA / Gonadotropins
H, Systemic hormonal preparations, excl sex hormones / H01AB / Thyrotropin
H01AC / Somatropin and somatropin agonist
H01AX / Other anterior pituitary lobe hormones and analogues
H04 / Pancreatic Hormones
H05AA / Parathyroid Hormone
H05BA / Calcitonin preparations
J, Anti-infectives for systemic use / J06 / Immune sera and immunoglobulins
J06BB16 / Palivizumab
J06BC01 / Nebacumab
L, Antineoplastic and immonomodulating agents / L01XC / Monoclonal antibodies
L01XX02 / Asparaginase
L01XX29 / Denileukin diftitoxin
L03AA / Colony stimulating factors
L03AB / Interferons
L03AC / Interleukins
L03AX11 / Tasonermin
L04AA02 / Muromonab-CD3
L04AA15 / Alefacept
L04AA21 / Efalizumab
L04AA23 / Natalizumab
L04AA24 / Abatacept
L04AA25 / Eculizumab
L04AA26 / Belimumab
L04AA28 / Belatacept
L04AB / TNF-alpha inhibitors
L04AC / Interleukin inhibitors
M, Musculo-skeletal system / M03AX / Other muscle relaxants
M05BC / Bone morphogenetic proteins
M05BX04 / Denosumab
M09AX02 / Autologous cultured chrondocytes
R, Respiratory system / R03DX05 / Omalizumab
S, Sensory Organs / S01AD08 / Fomivirsen
S01LA04 / Ranibizumab
S01LA05 / Alifercept
V, Various / V03AB24 / Digoxin Immune Fab
V03AF07 / Rasburicase
V03AF08 / Palifermin
V04CJ01 / Thyrotropin
V09IA04 / Votumumab
V09IA06 / Arcitumomab
V09IB02 / Satumomab
V09IB04 / Capromab
V09HA04 / Sulesomab
V10XA53 / Tositumomab
V10XX02 / Ibritumomab

2

Traceability of biopharmaceuticals (Final, June 2012)